• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

容量控制策略对连续性肾脏替代治疗的脓毒症相关性急性肾损伤患者生存的影响:一项随机对照试验的二次分析。

Volume control strategy and patient survival in sepsis-associated acute kidney injury receiving continuous renal replacement therapy: a randomized controlled trial with secondary analysis.

机构信息

Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, International Saint Mary's Hospital, Catholic Kwandong University, Incheon, Republic of Korea.

出版信息

Sci Rep. 2024 Jun 21;14(1):14284. doi: 10.1038/s41598-024-64224-z.

DOI:10.1038/s41598-024-64224-z
PMID:38902283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11190228/
Abstract

Optimal strategy for volume control and the clinical implication of achieved volume control are unknown in patients with sepsis-associated acute kidney injury (AKI) receiving continuous renal replacement therapy (CRRT). This randomized controlled trial aimed to compare the survival according to conventional or bioelectrical impedance analysis (BIA)-guided volume control strategy in patients with sepsis-associated AKI receiving CRRT. We also compared patient survival according to achieved volume accumulation rate ([cumulative fluid balance during 3 days × 100]/fluid overload measured by BIA at enrollment) as a post-hoc analysis. We randomly assigned patients to conventional volume control strategy (n = 39) or to BIA-guided volume control strategy (n = 34). There were no differences in 28-day mortality (HR, 1.19; 95% CI, 0.63-2.23) or 90-day mortality (HR, 0.99; 95% CI 0.57-1.75) between conventional and BIA-guided volume control group. In the secondary analysis, achieved volume accumulation rate was significantly associated with patient survival. Compared with the achieved volume accumulation rate of ≤  - 50%, the HRs (95% CIs) for the risk of 90-day mortality were 1.21 (0.29-5.01), 0.55 (0.12-2.48), and 7.18 (1.58-32.51) in that of  - 50-0%, 1-50%, and > 50%, respectively. Hence, BIA-guided volume control in patients with sepsis-associated AKI receiving CRRT did not improve patient outcomes. In the secondary analysis, achieved volume accumulation rate was associated with patient survival.

摘要

在接受连续性肾脏替代治疗(CRRT)的脓毒症相关急性肾损伤(AKI)患者中,容量控制的最佳策略以及实现的容量控制的临床意义尚不清楚。本随机对照试验旨在比较接受 CRRT 的脓毒症相关 AKI 患者中,常规或生物电阻抗分析(BIA)指导的容量控制策略的生存情况。我们还根据达到的容量累积率([第 3 天的累积液体平衡量×100]/在入组时 BIA 测量的液体超负荷)进行了事后分析,比较了患者的生存情况。我们将患者随机分配到常规容量控制策略组(n=39)或 BIA 指导的容量控制策略组(n=34)。两组的 28 天死亡率(HR,1.19;95%CI,0.63-2.23)或 90 天死亡率(HR,0.99;95%CI,0.57-1.75)均无差异。在次要分析中,达到的容量累积率与患者的生存显著相关。与达到的容量累积率≤-50%相比,达到的容量累积率为-50-0%、1-50%和>50%时,90 天死亡率的 HR(95%CI)分别为 1.21(0.29-5.01)、0.55(0.12-2.48)和 7.18(1.58-32.51)。因此,在接受 CRRT 的脓毒症相关 AKI 患者中,BIA 指导的容量控制并不能改善患者的结局。在次要分析中,达到的容量累积率与患者的生存相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2112/11190228/48c3493660e4/41598_2024_64224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2112/11190228/557fcfeb75df/41598_2024_64224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2112/11190228/48c3493660e4/41598_2024_64224_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2112/11190228/557fcfeb75df/41598_2024_64224_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2112/11190228/48c3493660e4/41598_2024_64224_Fig2_HTML.jpg

相似文献

1
Volume control strategy and patient survival in sepsis-associated acute kidney injury receiving continuous renal replacement therapy: a randomized controlled trial with secondary analysis.容量控制策略对连续性肾脏替代治疗的脓毒症相关性急性肾损伤患者生存的影响:一项随机对照试验的二次分析。
Sci Rep. 2024 Jun 21;14(1):14284. doi: 10.1038/s41598-024-64224-z.
2
Characteristics and Outcomes of Children and Young Adults With Sepsis Requiring Continuous Renal Replacement Therapy: A Comparative Analysis From the Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK).儿童和青少年脓毒症需要连续肾脏替代治疗的特征和结局:来自全球肾脏病肾脏替代治疗结局协作研究(WE-ROCK)的比较分析。
Crit Care Med. 2024 Nov 1;52(11):1686-1699. doi: 10.1097/CCM.0000000000006405. Epub 2024 Sep 11.
3
VolumE maNagement Under body composition monitoring in critically ill patientS on CRRT: study protocol for a randomized controlled trial (VENUS trial).连续肾脏替代治疗(CRRT)重症患者身体成分监测下的容量管理:一项随机对照试验的研究方案(VENUS试验)
Trials. 2018 Dec 12;19(1):681. doi: 10.1186/s13063-018-3056-y.
4
Hierarchical endpoints in critical care: A post-hoc exploratory analysis of the standard versus accelerated initiation of renal-replacement therapy in acute kidney injury and the intensity of continuous renal-replacement therapy in critically ill patients trials.重症监护中的分层终点:急性肾损伤中肾脏替代治疗标准启动与加速启动以及危重症患者连续肾脏替代治疗强度的事后探索性分析。
J Crit Care. 2024 Aug;82:154767. doi: 10.1016/j.jcrc.2024.154767. Epub 2024 Mar 11.
5
Mortality and associated risk factors in patients with blood culture positive sepsis and acute kidney injury requiring continuous renal replacement therapy-A retrospective study.血培养阳性脓毒症合并急性肾损伤需持续肾脏替代治疗患者的死亡率及相关危险因素:一项回顾性研究。
PLoS One. 2021 Apr 5;16(4):e0249561. doi: 10.1371/journal.pone.0249561. eCollection 2021.
6
The timing of continuous renal replacement therapy initiation in sepsis-associated acute kidney injury in the intensive care unit: the CRTSAKI Study (Continuous RRT Timing in Sepsis-associated AKI in ICU): study protocol for a multicentre, randomised controlled trial.重症监护病房中脓毒症相关性急性肾损伤患者开始持续肾脏替代治疗的时机:CRTSAKI研究(重症监护病房脓毒症相关性急性肾损伤的持续肾脏替代治疗时机):一项多中心随机对照试验的研究方案
BMJ Open. 2021 Feb 19;11(2):e040718. doi: 10.1136/bmjopen-2020-040718.
7
Increased 28-day mortality due to fluid overload prior to continuous renal replacement in sepsis associated acute kidney injury.脓毒症相关性急性肾损伤行连续肾脏替代治疗前液体超负荷与 28 天病死率增加相关。
Ther Apher Dial. 2022 Apr;26(2):288-296. doi: 10.1111/1744-9987.13727. Epub 2021 Aug 31.
8
Continuous Renal Replacement Therapy Improves Indicators and Short-Term Survival in People with AIDS Manifesting Sepsis and Acute Kidney Injury.连续性肾脏替代治疗改善艾滋病并发脓毒症和急性肾损伤患者的指标和短期生存率。
Jpn J Infect Dis. 2024 Jul 24;77(4):240-243. doi: 10.7883/yoken.JJID.2023.280. Epub 2024 Feb 29.
9
High-Dose Versus Conventional-Dose Continuous Venovenous Hemodiafiltration and Patient and Kidney Survival and Cytokine Removal in Sepsis-Associated Acute Kidney Injury: A Randomized Controlled Trial.高剂量与常规剂量连续静脉-静脉血液滤过对脓毒症相关性急性肾损伤患者和肾脏生存及细胞因子清除的影响:一项随机对照试验。
Am J Kidney Dis. 2016 Oct;68(4):599-608. doi: 10.1053/j.ajkd.2016.02.049. Epub 2016 Apr 12.
10
[Risk factors for mortality in intensive care unit patients with sepsis combined with acute kidney injury after continuous renal replacement therapy: secondary analysis of the data from a multicenter observational study].[连续性肾脏替代治疗后脓毒症合并急性肾损伤的重症监护病房患者的死亡危险因素:一项多中心观察性研究数据的二次分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Feb;31(2):155-159. doi: 10.3760/cma.j.issn.2095-4352.2019.02.007.

本文引用的文献

1
Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial.液体平衡和肾脏替代治疗启动策略:STARRT-AKI 试验的二次分析。
Crit Care. 2022 Nov 24;26(1):360. doi: 10.1186/s13054-022-04229-0.
2
When and why to start continuous renal replacement therapy in critically ill patients with acute kidney injury.急性肾损伤的危重症患者何时以及为何开始连续性肾脏替代治疗。
Kidney Res Clin Pract. 2021 Dec;40(4):566-577. doi: 10.23876/j.krcp.21.043. Epub 2021 Nov 1.
3
Mortality predictors in critically ill patients with acute kidney injury requiring continuous renal replacement therapy.
需要持续肾脏替代治疗的急性肾损伤重症患者的死亡预测因素。
Kidney Res Clin Pract. 2021 Sep;40(3):401-410. doi: 10.23876/j.krcp.20.205. Epub 2021 Jul 5.
4
Assessment of body fluid in critically ill patients with acute kidney injury requiring continuous renal replacement therapy.对需要持续肾脏替代治疗的急性肾损伤重症患者的体液评估。
Kidney Res Clin Pract. 2020 Dec 31;39(4):381-383. doi: 10.23876/j.krcp.20.229.
5
Fluid Overload and Mortality in Adult Critical Care Patients-A Systematic Review and Meta-Analysis of Observational Studies.成人重症监护患者液体超负荷与死亡率:观察性研究的系统评价和荟萃分析。
Crit Care Med. 2020 Dec;48(12):1862-1870. doi: 10.1097/CCM.0000000000004617.
6
Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.急性肾损伤中肾脏替代治疗的启动时机。
N Engl J Med. 2020 Jul 16;383(3):240-251. doi: 10.1056/NEJMoa2000741.
7
Fluid removal associates with better outcomes in critically ill patients receiving continuous renal replacement therapy: a cohort study.连续肾脏替代治疗的危重症患者中,液体清除与更好的结局相关:一项队列研究。
Crit Care. 2020 Jun 1;24(1):279. doi: 10.1186/s13054-020-02986-4.
8
Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery.血管活性-正性肌力评分与心脏手术后发病率和死亡率的预测。
Br J Anaesth. 2019 Apr;122(4):428-436. doi: 10.1016/j.bja.2018.12.019. Epub 2019 Feb 18.
9
Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.急性肾损伤合并脓毒症患者肾脏替代治疗时机。
N Engl J Med. 2018 Oct 11;379(15):1431-1442. doi: 10.1056/NEJMoa1803213.
10
Deresuscitation of Patients With Iatrogenic Fluid Overload Is Associated With Reduced Mortality in Critical Illness.医源性液体超负荷患者的复苏与危重病患者死亡率的降低有关。
Crit Care Med. 2018 Oct;46(10):1600-1607. doi: 10.1097/CCM.0000000000003276.